ロード中...
Gene therapy for primary immune deficiencies: a Canadian perspective
The use of gene therapy (GT) for the treatment of primary immune deficiencies (PID) including severe combined immune deficiency (SCID) has progressed significantly in the recent years. In particular, long-term studies have shown that adenosine deaminase (ADA) gene delivery into ADA-deficient hematop...
保存先:
| 出版年: | Allergy Asthma Clin Immunol |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5327566/ https://ncbi.nlm.nih.gov/pubmed/28261277 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13223-017-0184-y |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|